Despite data suggesting that individuals with multiple myeloma can benefit from receiving several lines of therapy, and guidelines recommending...
Myeloma NZ
Single-cell Profiling in Multiple Myeloma May Improve Diagnosis, Treatment, Study Suggests
Analysis of thousands of individual cells in multiple myeloma patients allows for a much more precise diagnosis — distinguishing asymptomatic,...
Lenalidomide Maintenance Therapy for Multiple Myeloma
Orally administered lenalidomide, a second-generation antimyeloma thalidomide analog, is a workhorse in contemporary management of multiple myeloma:...
Myeloma Study Makes the Case for a New Standard for Predicting Long-Term Outcome
As new treatments for multiple myeloma have extended patient survival—from an average of three years to more than 10 in some cases—physicians and...
Increased Risk of Myeloma in African Americans Driven By Higher Rates of 3 Disease Subtypes
Multiple myeloma (MM)Â and monoclonal gammopathy of undetermined significance (MGUS), a precursor to MM, are 2 to 3 times more common in African...
THE ELUSIVE C-WORD: CURE?
Until now, myeloma patients whose cancer was resistant to commonly used treatment methods and drugs had nowhere to turn. But a Phase 2 CAR T-cell...
CAR T Cell Therapy Market to Reflect Impressive Growth Rate
Increasing incidence of cancer and rising number of patients showing response failure to alternative treatments is expected to foster growth of the...
Takeda to Collaborate With MSKCC on CAR-T Therapies for Multiple Myeloma
On January 3, 2019, Takeda announced multiple research collaborations involving the development of chimeric antigen receptor T-cell (CAR-T)...
Latest technology can identify Multiple Myeloma cells faster than ever
Multiple myeloma is a type of blood cancer that affects the plasma cells located in the bone marrow of the body. During an infection, when B cells...
Multiple Myeloma Drugs Market: How Will Be the Industry Growth by 2023
The 'Global and Southeast Asia Multiple Myeloma Drugs Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the...
Aplidin Approved in Australia for Relapsed or Refractory Multiple Myeloma
Treatment with Aplidin (plitidepsin) in combination with dexamethasone was approved in Australia for multiple myeloma patients who have failed or...
Next-Generation BCMA CAR T-cell Therapy Effective for Heavily Pretreated Myeloma
The anti-BCMA CAR T-cell therapy bb21217 demonstrated an objective response rate (ORR) of 83.3%, with a very good partial response (VGPR) or better...